Jeff Settleman
Overview
Explore the profile of Jeff Settleman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
65
Citations
10807
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rudolph J, Settleman J, Malek S
Cancer Discov
. 2021 Apr;
11(4):815-821.
PMID: 33811118
Technology advancement and the courage to challenge dogma have been key elements that have continuously shifted druggability limits. We illustrate this notion with several recent cancer drug-discovery examples, while also...
2.
Singh A, Greninger P, Rhodes D, Koopman L, Violette S, Bardeesy N, et al.
Cancer Cell
. 2021 Mar;
39(3):441-442.
PMID: 33689705
No abstract available.
3.
Settleman J, Fernandes Neto J, Bernards R
Cancer Discov
. 2021 Mar;
11(5):1016-1023.
PMID: 33648929
Most experimental cancer drugs ultimately fail during the course of clinical development, contributing to the high cost of the few that are granted regulatory approval. Moreover, approved drugs often deliver...
4.
Deuker M, Lewis K, Ingaramo M, Kimmel J, Buffenstein R, Settleman J
Sci Rep
. 2020 Apr;
10(1):6966.
PMID: 32332849
The naked mole-rat is a subterranean rodent, approximately the size of a mouse, renowned for its exceptional longevity (>30 years) and remarkable resistance to cancer. To explore putative mechanisms underlying...
5.
Chin T, Boopathy G, Man E, Clohessy J, Csizmadia E, Quinlan M, et al.
Theranostics
. 2020 Mar;
10(6):2727-2743.
PMID: 32194831
Oncogene-addicted cancers are predominantly driven by specific oncogenic pathways and display initial exquisite sensitivity to designer therapies, but eventually become refractory to treatments. Clear understanding of lung tumorigenic mechanisms is...
6.
Finn K, Martin S, Settleman J
Cancer Res
. 2019 Oct;
80(1):79-90.
PMID: 31641034
Despite the remarkable clinical efficacy demonstrated by molecularly targeted cancer therapeutics, the benefits are typically temporary due to the emergence of acquired drug resistance. This has spurred a massive effort...
7.
Sulahian R, Kwon J, Walsh K, Pailler E, Bosse T, Thaker M, et al.
Cell Rep
. 2019 Oct;
29(1):118-134.e8.
PMID: 31577942
The mitogen-activated protein kinase (MAPK) pathway is a critical effector of oncogenic RAS signaling, and MAPK pathway inhibition may be an effective combination treatment strategy. We performed genome-scale loss-of-function CRISPR-Cas9...
8.
Wang V, Xue J, Frederick D, Cao Y, Lin E, Wilson C, et al.
Clin Cancer Res
. 2019 Sep;
25(23):7202-7217.
PMID: 31515463
Purpose: Combined MAPK pathway inhibition using dual BRAF and MEK inhibitors has prolonged the duration of clinical response in patients with BRAF-driven tumors compared with either agent alone. However, resistance...
9.
Mehta A, Hua K, Whipple W, Nguyen M, Liu C, Haybaeck J, et al.
Sci Signal
. 2017 Sep;
10(496).
PMID: 28900044
mutant non-small cell lung cancer (NSCLC) may be classified into epithelial or mesenchymal subtypes. Despite having the same "driver" mutation, mesenchymal NSCLCs are less responsive than are epithelial NSCLCs to...
10.
Guler G, Tindell C, Pitti R, Wilson C, Nichols K, KaiWai Cheung T, et al.
Cancer Cell
. 2017 Aug;
32(2):221-237.e13.
PMID: 28781121
Maintenance of phenotypic heterogeneity within cell populations is an evolutionarily conserved mechanism that underlies population survival upon stressful exposures. We show that the genomes of a cancer cell subpopulation that...